Antidepressant Market Crosses Rs 2,842 Crore, But Are More Indians Getting Better?
India's antidepressant and mood-drug market grew 8.63 per cent to Rs 2,842.1 crore in the 12 months ended September 2026, even as unit sales declined 0.76 per cent. Doctors say the figures must be viewed alongside unmet treatment needs, changing prescribing patterns and concerns over self-diagnosis and medication adherence.
New Delhi witnessed a significant rise in India's antidepressant and mood-drug market, reaching Rs 2,842 crore in the 12 months ending September 2026, an 8.63 percent increase from Rs 2,616.3 crore in the same period a year prior. However, unit sales have declined by 0.76 percent during this period. The divergence between rising market value and declining unit sales raises questions about whether the increase in antidepressant usage signifies a growing mental health crisis, enhanced accessibility to treatment, or a shift in prescribing practices.
PharmaTrac data reveals that the market has expanded since September 2022, when it stood at Rs 1,972.6 crore. Nonetheless, the increase in market value is not solely attributable to more patients receiving antidepressants. Several factors could contribute to this trend. Escitalopram combined with Clonazepam remains the largest product in the category, with sales growth of 10.51 percent to Rs 710.4 crore, accounting for approximately one-quarter of the market.
Similarly, Sertraline, Desvenlafaxine, and Duloxetine experienced substantial growth, with sales rising 23.45 percent, 20.45 percent, and 8 percent, respectively.
However, it is challenging to determine precisely how much changes in pricing or shifts in product mix are driving the growth in antidepressant sales. Additional analysis is necessary to establish the extent to which various factors, such as better recognition and diagnosis, longer treatment durations, or increased repeat prescriptions, are influencing the trend.
Despite the uncertainties, doctors agree that the rising sales of antidepressants reflect genuine treatment needs, better recognition of mental health issues, and longer treatment durations among patients who respond positively to treatment.
Written by urgent.news from ETHealthworld's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
